FDAnews
www.fdanews.com/articles/101682-study-supports-cadstream-for-the-evaluation-of-kinetics-in-breast-mri

Study Supports CADstream for the Evaluation of Kinetics in Breast MRI

November 30, 2007

A study by the Seattle Cancer Care Alliance and the University of Washington suggests that the CADstream system’s patented “worst curve” algorithm for analyzing kinetics may assist in determining malignancy.

The study, presented at the Radiological Society of North America’s meeting last week, focused on the evaluation of kinetics and found that the most suspicious curve as identified by CADstream was significantly different between benign and malignant lesions, Confirma, which markets the product, said. The study also found that any washout enhancement was associated with malignancy in nearly half of the lesions.

The data supports the recommendation of the American College of Radiology’s Breast Imaging Reporting and Database System Atlas for breast MRI to report the “worst looking” curve, the company said.